Corcept’s Lifyorli Extends Survival in Ovarian Cancer, Gains NCCN Nod — Corcept Therapeutics Incorporated

Event summary

Corcept’s Lifyorli (relacorilant) plus nab-paclitaxel improved overall survival by 4.1 months in platinum-resistant ovarian cancer patients (16.0 vs. 11.9 months).
The ROSELLA trial met dual primary endpoints, reducing risk of death by 35% (HR 0.65, p=0.0004) and disease progression by 30% (HR 0.70, p=0.0076).
Lifyorli gained NCCN preferred regimen status and FDA approval in March 2026 for platinum-resistant ovarian cancer.
The combination was well-tolerated, with adverse events comparable to nab-paclitaxel monotherapy.
Corcept submitted a Marketing Authorisation Application (MAA) to the EMA for European approval.

The big picture

Corcept’s success with Lifyorli validates cortisol modulation as a viable oncology strategy, particularly in chemoresistant tumors. The NCCN endorsement and FDA approval position the therapy as a new standard of care, while the European filing could unlock additional revenue streams. The approach may extend beyond ovarian cancer to other glucocorticoid receptor-expressing malignancies.

What we're watching

Regulatory Momentum: Whether the EMA will follow the FDA’s approval path for Lifyorli in Europe, expanding market access.
Commercial Execution: How Corcept scales patient access and payer adoption for Lifyorli in the U.S.
Pipeline Expansion: The pace at which Corcept advances relacorilant into other cortisol-sensitive cancers.